Olanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar rats by Evers, S. S. et al.
  
 University of Groningen
Olanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in
female Wistar rats
Evers, S. S.; Calcagnoli, F.; van Dijk, G.; Scheurink, A. J. W.
Published in:
Pharmacology, Biochemistry and Behavior
DOI:
10.1016/j.pbb.2010.05.029
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2010
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Evers, S. S., Calcagnoli, F., van Dijk, G., & Scheurink, A. J. W. (2010). Olanzapine causes hypothermia,
inactivity, a deranged feeding pattern and weight gain in female Wistar rats. Pharmacology, Biochemistry
and Behavior, 97(1), 163-169. https://doi.org/10.1016/j.pbb.2010.05.029
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Pharmacology, Biochemistry and Behavior 97 (2010) 163–169
Contents lists available at ScienceDirect
Pharmacology, Biochemistry and Behavior
j ourna l homepage: www.e lsev ie r.com/ locate /pharmbiochembehOlanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight
gain in female Wistar rats
S.S. Evers ⁎, F. Calcagnoli, G. van Dijk, A.J.W. Scheurink
Department of Neuroendocrinology, University of Groningen, The Netherlands⁎ Corresponding author. Department of Neuroendocr
gen, Kerklaan 30, 9751 NN Haren, The Netherlands. Tel
E-mail address: s.s.evers@rug.nl (S.S. Evers).
0091-3057/$ – see front matter © 2010 Elsevier Inc. Al







RatOlanzapine is an a-typical antipsychotic drug antagonizing predominantly 5-HT and dopamine, but also
histamine, muscarin, and α-adrenergic receptors. In humans, Olanzapine induces weight gain and increases
the risk of type 2 diabetes. The underlying mechanisms of Olanzapine-induced weight gain are unclear. To
study this we administered Olanzapine (5 mg/kg) in female Wistar rats on a medium fat diet for 14 days via
a permanent gastric catheter twice a day, just prior to the onset and at the middle of dark phase. Food and
water intake, locomotor activity and body temperature were measured. Olanzapine acutely induced
hypothermia, markedly decreased locomotor activity and increased body weight during 14 days of
treatment. Olanzapine treatment did not result in an alteration of 24 h food intake, but diurnal patterns of
feeding behavior and body temperature were dramatically changed. We conclude that in female Wistar rats
Olanzapine has an acute hypothermic effect, that the effect of Olanzapine on feeding behavior is secondary to
the effect on activity, and that Olanzapine-induced weight gain is primarily the result of reduction in
locomotor activity.inology, University of Gronin-
.: +31 50 363 2333.
l rights reserved.© 2010 Elsevier Inc. All rights reserved.1. Introduction
Over the recent years, considerable attention has been paid to
the metabolic side effects of the a-typical antipsychotic drug
(APD) Olanzapine. Olanzapine is primarily designed to be antagonistic
on 5-HT2A/C and dopamine receptors (Bymaster et al., 1996a,b) for
treatment of schizophrenia and bipolar disorder. However, besides its
effect on psychotic illnesses, Olanzapine in humans causes body
weight gain and increases the risk of developing type 2 diabetes
(Baptista et al., 2002; Ananth et al., 2002; Caballero, 2003).
The underlying mechanisms are still unclear, as several contra-
dictions with respect to Olanzapine's actions on metabolic pathways
have been reported in humans or animals (Pouzet et al., 2003; Cohen
and Perel, 2004; Aichhorn et al., 2006; Choi et al., 2007). Olanzapine
does not only act on serotonin or dopamine receptors, but has
antagonistic properties on histaminergic, muscarinic, and α-adrener-
gic receptors as well (Bymaster et al., 1996a,b, 1999). Receptors
targeted by Olanzapine are located in CNS neuronal networks
involved in energy homeostasis (Sawchenko et al., 1983; Zubieta
and Frey, 1993; Richtand et al., 1995; Tavares et al., 1996; Yoshimatsu,
2008), but can also be found throughout the digestive tract (Bymasteret al., 2001), in skeletal muscle (Hajduch et al., 1999) and adipose
tissue (Yang et al., 2009). The wide-spread distribution of putative
action site for Olanzapine explains the multitude of mechanisms and
various time–dose relationships that have been reported with
Olanzapine treatment in humans.
Experimental studies in animals on the mechanisms underlying
Olanzapine's metabolic effects also provide confusing data. Female
rats appear to increase body weight more profoundly than male rats
(Cooper et al., 2005, 2007) and this increase in body weight,
predominantly adipose tissue, may be related to a decreased level of
physical activity (the sedative effect of Olanzapine), or by an increase
in food intake, although again contradictory results have been found
(Lee and Clifton, 2002; Victoriano et al., 2009; Davoodi et al., 2009).
Furthermore, Olanzapine has also been shown to induce hypothermia
(Oerther and Ahlenius, 2000) and to block orexin-A induced
hyperthermia (Monda et al., 2008), but these effects have not been
investigated in the face of Olanzapine's effect on body weight gain.
One of the gaps between the pre-clinical rodent studies and
human clinical studies is the huge discrepancy between dosing. The
main cause is that Olanzapine's half life time in rats is about 2.5 h
compared to 21–54 h in human (Kapur et al., 2003). Therapeutic
doses in human are aimed to reach 65–80% D2-receptor occupancy
(Farde et al., 1988; Kapur et al., 2003; Naiker et al., 2006), to reach
such levels in male Sprague–Dawley rats (250–275 g) Kapur et al.
show that Olanzapine needs to be administered continuously using an
osmotic minipump at 7.5 mg/kg/day (Kapur et al., 2003). However,
Van der Zwaal et al. showed that Olanzapine is vulnerable to
degradation at body temperature therefore long term infusion of
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et al., 2008). Rat studies show the most pronounced effects on
food intake and body weight gain when Olanzapine is administered at
1–2 mg/kg twice a day (Cooper et al., 2005; Davoodi et al., 2009).
Whereas studies focusing on central receptor activity in speciﬁc brain
areas (Robertson and Fibiger, 1996; Bymaster et al., 1996b; Li et al.,
1998; Rollema et al., 2000; Lacroix et al., 2003; Angelucci et al., 2005)
or Olanzapine's effect on thermogenesis (Oerther and Ahlenius, 2000;
Monda et al., 2008; Stefanidis et al., 2009) use often a single ad-
ministration up to 10 mg/kg.
In this study, we re-evaluated a number of potential mechanisms,
i.e. food intake patterning, locomotor activity, body temperature, by
which Olanzapine may induce weight gain in female rats subjected to
a high-fat diet. To amplify Olanzapine's effect on locomotor activity
and thermogenesis we decided to administer a dose of 5 mg/kg b.i.d.
of Olanzapine. The main outcome of this study paradigm is that
weight gain by Olanzapine treatment is predominantly caused by
reduced locomotor activity combined with dramatic derangements of
several circadian behavioral and physiological patterns.2. Materials and methods
2.1. Animals
All procedures involving animal care and experimental procedures
have been approved by the Animal Experimentation Committee of the
University of Groningen. Female Wistar rats (232±3.5 g; on arrival),
obtained from Harlan (Horst, NL) were individually housed in clear
Plexiglass cages (25⁎25⁎30 cm) on a plastic ﬂoor with wood chip
bedding. Female rats were chosen based on the results of Cooper et al.
(2005, 2007). Room temperature was controlled at 22±2 °C, under a
12:12 h light–dark cycle (lights off at 11:00 AM). Animals had one
week to adapt to the new environment before undergoing surgery,
the baseline measurements started one week after surgery when all
animals had surpassed their pre-surgical body weight. Prior to
drug treatment, animals had ad libitum access to standard chow
(3.8 kcal/g) and water. From day 0 (the start of drug treatment) a
medium fat diet with lard (4.7 kcal/g; 45% fat, Arie Blok Diets,
Woerden, NL) was given to all animals to stimulate weight gain.2.2. Drugs
Olanzapine (as powder) was kindly provided by Solvay Pharma-
ceuticals (Fournier Laboratory, France). To obtain a daily administra-
tion of 10 mg/kg Olanzapine was diluted to 1.5 mg/ml in 0.9% NaCl
saline. Olanzapine was ﬁrst dissolved in saline using 1 M HCl and
adjusted to pH 6.5 using 1 M NaOH. Animals were administered
Olanzapine or saline twice a day, prior to the dark phase and 6 h after
lights went off.2.3. Surgical procedure
Animals were equipped with a permanent gastric catheter for
stress-free intragastric drug administration and a telemetry transmit-
ter (model TA10TA-F40, Data Sciences, St. Paul, MN) in the abdominal
cavity for continuous temperature and activity registration (Meerlo
et al., 1996). Surgical procedures were performed by using isoﬂurane-
O2/N2O gas-anesthesia. A silicon catheter (1.40-mm OD, 0.80-mm ID)
was inserted through the gastric wall at the level of the corpus,
extending 0.5 cm into the gastric lumen. The catheter was drawn
subcutaneous towards the head where it was ﬁxed to the skull
with dental cement (Wielinga et al., 2005). Animals were given
0.1 ml Finadine s.c. for analgesia and 0.25 ml penicillin s.c. to prevent
infection.2.4. Circadian registration
Core body temperature and activity were recorded throughout the
duration of the experiment using radiotelemetry. Telemetry signals
were received by separate responder plates (model RA1010, Data
Sciences) underneath each cage. Data was collected every 5 min by a
PC and analyzed by using specialized recording and analyses software
(Dataquest IV, Data Sciences) (Meerlo et al., 1996).
2.5. Experimental set-up
Data was collected starting at 7 days before the start of drug
administration (day 0). Olanzapine was administered intragastric
twice a day at CT 11.5 (CT 12=lights off at 11 AM) and at CT 18.
From day 0 all animals were switched from the standard lab chow
diet to the medium fat diet. Body weight, food intake and water
intake was measured every day at CT 11.5 for 14 days. At day 17 the
animals were individually housed in a specialized cage for contin-
uous registration of food intake and locomotor activity for 3 days
(TSE Systems GmbH, Bad Homburg, Germany) to monitor circadian
feeding patterns, meal sizes and meal numbers. Circadian food intake
patterns were calculated as an average of the last two consecutive
days, the ﬁrst day was used for adaptation. These plexiglass cages
(40⁎23⁎15 cm) consist of a sensitive weight balanced food station
(stainless steel food container for standard size food pellets); water
bottles were weighed once a day prior to dark phase. Olanzapine
administration was continued all the time twice a day at the above
mentioned time points. At the end of the experiment rats had ad lib
access to two bottles with either a 10% (g/vol) sucrose solution or a
water bottle for 24 h in a two-bottle-preference test. The bottles
were presented at CT 12 and intake was measured at time point 6
and 24 h after presentation.
2.6. Data analyses
Activity data was analyzed as a percentual change of activity
relative to baseline per individual. Baseline was calculated as the
average activity per day during oneweek prior to day 0 per individual,
this average was set as 100%. All activity data were then expressed as
percentage of this baseline value.
All data are expressed as averages±SEM. Statistical analyses were
performed using repeated measures (rm)ANOVA between-subjects
for time dependent analyses. A multivariate (m)ANOVA between-
subjects test was used to calculate signiﬁcance at different time points
during time related treatment. Activity and body temperature data
were analyzed from baseline average to day 14 of treatment. Because
average daily activity and body temperature data consist of a too large
amount of data points, rmANOVA was performed for four consecutive
6 h time frames. All data expressed without a time dependent factor
are analyzed using One-way ANOVA test. All statistical analyses were




Fig. 1 presents 24 h food intake, activity, body temperature and the
changes in body weight in the Olanzapine-treated animals and
controls before and during treatment. Olanzapine treatment (5 mg/
kg b.i.d.) stimulated body weight gain (Fig. 1a) which was signiﬁcant
after 6 days (mANOVA: Pb0.05) and persisted during the rest of
treatment (rmANOVA: F14,112=3.893, Pb0.01). The increase of body
weight was not accompanied by changes in 24 h food intake (Fig. 1b)
or average 24 h body temperature (Fig. 1d). Olanzapine decreased the
activity of the animals during 14 days of treatment (Fig. 1c), this was
Fig. 1. a) Effects of intragastric administration of Olanzapine (n=5) or saline (n=5) on bodyweight gain in grams, expressed as changes from day 0, the start of drug administration.
b) The effect of Olanzapine (n=5) and saline (n=5) on 24 h food intake, expressed as kcal. Day−7 to−1 show standard chow intake, days 1 to 14 show medium fat diet intake.
c) The effect of Olanzapine (n=4) and saline (n=4) on 24 h activity expressed as a percentage of baseline activity. d) The effect of Olanzapine (n=5) and saline (n=5) on average
24 h body temperature. In all graphs, Olanzapine is presented as ﬁlled squares and saline controls as open circles. Signiﬁcance is presented as * Pb0.05, and #Pb0.01.
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in the control rats (rmANOVA: F15,90=2.914, Pb0.01; mANOVA:
Pb0.05 and Pb0.01).
Fig. 2 presents both the 24 water intake and the cumulative intake
over days 0–14 during Olanzapine or saline treatment. The switch
from the standard lab chow to the medium fat diet led to a reduction
in water intake in the controls but not in Olanzapine-treated animals
(Fig. 2). Both thewater intake per day (F1,8=8.304,*Pb0.05; One-way
ANOVA) and 14 day cumulative water intake (rmANOVA: F15,120=
2.703, Pb0.01) were signiﬁcantly increased in the Olanzapine-treated
animals in comparison to the control animals.
3.2. Telemetry data
The average activity and body temperature over both the 12 h dark
and 12 h light phase were calculated to investigate the diurnal
rhythms in activity, food intake and body temperature. Dark and light
phase activities are expressed as percentage of average 24 h activity inFig. 2. a) The effect of Olanzapine (n=5) and saline (n=5) treatment on 24 h water intake
treatment. Olanzapine is presented as ﬁlled squares, control as open circles. Signiﬁcance isthe baseline measurements in the week before day 0. Fig. 3a–b shows
that Olanzapine signiﬁcantly reduced the activity in the dark period
(Fig. 3a, rmANOVA: F15,90=5.558, Pb0.01), while light phase activity
was unaffected (Fig. 3b).
Fig. 3c–d shows that Olanzapine treatment led to a signiﬁcant
reduction in body temperature in the dark phase (Fig. 3c, rmANOVA:
F15,120=8.630, Pb0.01), and a signiﬁcant increase in the light phase
(Fig. 3d, rmANOVA: F15,120=4.231, Pb0.01). Fig. 4 provides more
detailed information (every 5 min) on body temperature and activity.
Drug administration (indicated by arrows) caused an acute signiﬁcant
drop of both body temperature (rmANOVA CT 12–18: F71,568=12.144,
Pb0.01; and CT 18–0: F71,426=2.13, Pb0.01) and locomotor activity
(CT 12–18; rmANOVA: F71,426=1.778, Pb0.01; and CT 18–0: F71,426=
2.13, Pb0.01), which persisted throughout the dark period. In
the light period Olanzapine treatment caused an increase in body
temperature (Fig. 4b, rmANOVA CT 0–6: F71,568=9.184 Pb0.01, and
CT 6–12: F71,568=11.664, Pb0.01) with no signiﬁcant changes in
activity (Fig. 4a). Fig. 4 also shows a diurnal rhythm in the control(WI), expressed as ml. b) Cumulative water intake after 14 days of Olanzapine or saline
presented as * Pb0.05, and #Pb0.01.
Fig. 3. a and b) The effect of Olanzapine and saline on locomotor activity in the dark (a) and light (b) period. Activity is expressed as a percentage of total 24 h activity during the
baseline period. c and d) The effect of Olanzapine and saline on body temperature in the dark (c) and light (d) period. In all graphs, Olanzapine is presented as ﬁlled squares, controls
as open circles. Signiﬁcance is presented as * Pb0.05, and #Pb0.01.
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dark phase (11:00 h–23:00 h) compared to the light phase, This daily
rhythm is disturbed by the administration of Olanzapine.
3.3. Food registration data
At days 17 and 18, feeding behavior was continuously monitored
during two consecutive days. Fig. 5a gives the average intake over these
two days is per hour. There weremarked differences in feeding patterns
betweenbothgroups (rmANOVA: F23,414=3.864, Pb0.01). Fig. 5b shows
the cumulative food intake over 24 h and reveals that there is a decrease
of food intake during the second half of dark phase, while food intake
during the light period is increased when compared to control values.
The 24 h cumulative data (Fig. 5b) shows that Olanzapine reduced
food intake during the dark (Controls: 45.45±3.22 kcal; Olanzapine:
28.72±2.14 kcal; One-way ANOVA: F1,18=18.739, Pb0.01). During the
light period Olanzapine increased food intake relative to control
treatment (Controls: 19.74±2.80 kcal; Olanzapine: 27.45±1.69 kcal.Fig. 4. a) The effect of Olanzapine and saline administration on locomotor activity expresse
baseline activity per 5 min per 24 h. b) The effect of Olanzapine and saline administration
treatment. Arrows indicate the time of drug administration. Lights turned off at 11:00 h. OlANOVA: F1,18=5.546, Pb0.05).During thedarkperiodmeal size (Fig. 5c)
was decreased by Olanzapine (One-way ANOVA: F1,18=4.606, Pb0.05),
without signiﬁcant effects on meal number (Fig. 5d).
3.4. First day of treatment
The data of day 0, the day that all animals switched to the new
diet and received their ﬁrst injection of saline or Olanzapine, are
presented in Table 1. The switch from lab chow to medium fat diet led
to a signiﬁcant increase in food intake in the control group
(chow=58.35±3.55 kcal, medium fat diet=100.58±3.82 kcal; One-
way ANOVA: F1,8=64.150, Pb0.01) but not in the Olanzapine group
(chow=59.39±4.57 kcal, medium fat diet=75.20±5.56 kcal; One-
way ANOVA: F1,8=4.826, P=0.06).Water intake was lower compared
to baseline levels, with no difference between groups. Locomotor
activity and body temperature were decreased by Olanzapine when
compared to control. This amount of activity within the Olanzapine
group during the light phase was signiﬁcantly lower (F1,6=10.569,d as average of 14 days of treatment. Activity is expressed as the percentage of average
on body temperature (°C) expressed as the average body temperature over 14 days of
anzapine is presented as ﬁlled squares, controls as open circles.
Fig. 5. a and b) The effect of Olanzapine and saline treatment on circadian food intake (kcal) per hour (a) or 24 h cumulative food intake (kcal). Lights turned off at 11:00 h and turned
on at 23:00 h. Signiﬁcance is presented as *Pb0.05. c) and d) The effect of Olanzapine and saline on averagemeal size (a) andmeal number (d) in the dark and light period, expressed
as an average of two consecutive days. Signiﬁcance is presented as *Pb0.05. All Olanzapine data is presented as ﬁlled squares/bars, controls as open circles/bars.
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average light phase activity of 14 day Olanzapine treatment. 24 h body
temperature is signiﬁcantly decreased (F1,8=83.175, Pb0.05; One-
way ANOVA) in the ﬁrst day of Olanzapine treatment compared to the
average of 14 day treatment.
3.5. Sucrose preference
At the end of experiment a two bottle preference test for 10%
(g/vol) sucrose solution was performed. Table 2 shows that sucrose
intake was signiﬁcantly higher in the controls (6h=17.52±2.51 ml;
24h=53.52±9.18 ml) when compared to Olanzapine (6h=4.24±
1.61 ml; 24h=21.76±4.22 ml) treated animals, both after 6 (F1,8=
19.851, Pb0.01, One-way ANOVA) and 24 h (F1,8=9.879, Pb0.05,
One-way ANOVA).
4. Discussion and conclusions
In this study in female Wistar rats we found that chronic
Olanzapine treatment led to a signiﬁcant weight gainwithout changes
in 24 h food intake. Olanzapine dramatically reduced locomotor
activity, caused an acute hypothermia and completely deranged the
circadian patterns in food intake.
Since there were no changes in 24 h food intake, one may argue
that the Olanzapine-induced weight gain might be secondary to theTable 1
Responses at ﬁrst day of treatment. The effect of Olanzapine or Control treatment on
24 h food andwater intake, average 24 h activity, and average 24 h body temperature at
the ﬁrst day of treatment (day 0).
Control Olanzapine F1,8(*1,6) P-value
Food intake (kcal) 100.58±3.82 75.20±5.56 14.155 b0.01
Water intake (ml) 13.20±0.92 15.40±1.29 1.936
Activity (%) 105.11±10.22 42.26±4.72 *31.191 b0.01
Body temperature (°C) 37.59±0.03 37.23±0.03 115.852 b0.001marked reduction in locomotor activity, previously described as the
sedative effect of Olanzapine (Ahnaou et al., 2003). Fig. 4 shows in
detail the acute reduction of locomotor activity after Olanzapine
administration, which persisted throughout the duration of the
experiment. Comparable results of reduction in activity by Olanzapine
have been reported before in both rats (Hillebrand et al., 2005;
Stefanidis et al., 2009) and humans (Callaghan et al., 1997;
Putzhammer et al., 2005; Roerig et al., 2005).
Olanzapine did not affect 24 h food intake in this study, but we
observed marked differences between dark and light period feeding
patterns by Olanzapine. Food intake was markedly reduced in the
dark phase and was increased in the light phase. It is tenable to
assume that the reduction in dark phase food intake is mainly caused
by the sedative effect of Olanzapine. The increased food intake in the
normally inactive light phase could then be considered as a
compensatory homeostatic response to compensate controlling total
24 h food intake. These marked derangements in day/night food
intake support previous observations by Lee and Clifton (2002) who
found that Olanzapine failed to affect 22 h food intake but also noticed
that the size of the ﬁrst meal as well as the latency to eat was reduced
after Olanzapine administration. In the present study we found that
Olanzapine during the dark phase reduced meal size, with a small but
not signiﬁcant reduction in meal frequency.
The effects of Olanzapine on body temperature were remarkably
similar to the effects on feeding: there was no effect on average 24 h
body temperature but there were marked derangements of the dark
and light phase patterns. As shown is Fig. 4 in detail, Olanzapine
induced a dramatic hypothermic response immediately afterTable 2
Sucrose preference. The effect of Olanzapine and Control treatment on 6 and 24 h
sucrose intake during a two-bottle preference test.
Control Olanzapine F1,8 P-value
Sucrose intake (ml) 6 h 17.52±2.51 4.24±1.61 19.851 b0.01
24 h 53.52±9.18 21.76±4.22 9.879 b0.05
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this reduction in body temperature was secondary to the sedative and
hypophagic effects of Olanzapine (i.e., leading to reduced activity- and
diet-induced thermogenesis). Instead, data from literature suggest
that the hypothermia may be explained by a direct inhibitory effect of
Olanzapine on sympathetic outﬂow and brown adipose tissue (BAT)
thermogenesis (Oerther and Ahlenius, 2000). Indeed, Olanzapine
decreases uncoupling protein 1 (UCP1) expression in BAT and
increases Fos expression in orexin-A positive neurons in perifornical
region (PeF) of the lateral hypothalamic area (LHA) projecting to the
BAT (Stefanidis et al., 2009). Likewise, Olanzapine inhibits the
increase in sympathetic activity after icv orexin-A administration
(Monda et al., 2008). Taken together, these data suggest that the
Olanzapine-induced hypothermia has, at least in part, a centrally
regulated origin, directly related to the orexin-A system at the level of
the lateral hypothalamus (LHA).
Body temperature was signiﬁcantly increased during the light
period (Figs. 3 and 4). This increase was probably the result of an
increased diet-induced thermogenesis caused by the elevated food
intake in the light period in the Olanzapine-treated animals.
Olanzapine treatment reduced the intake of sucrose in a two-
bottle-preference test, suggesting a reduced motivation for palatable
foods (Table 2). Likewise, Olanzapine prevented the normal increase
in food intake (as seen in the control animals) on day 0, the ﬁrst day
that the animals were confronted with the palatable medium fat diet
(Table 1) These ﬁndings might be explained by Olanzapine's
antagonist action on the dopaminergic system, because D2-receptor
antagonism has been shown to reduce sucrose preference (Yu et al.,
2000). Since Olanzapine has been shown to increase swimming
activity in a forced swim test (Molina-Hernandez et al., 2009), one
may conclude that Olanzapine does not inhibit activity per se, but may
predominantly inhibit the motivation to be active.
In this studywe used a relatively high dose of Olanzapine (5 mg/kg
b.i.d). Studies performed by Cooper et al. (2005) and Davoodi et al.
(2009) revealed that lower dose (2–4 mg/kg/day) might lead to a
higher increase in body weight, partly the result of increased food
intake. Oerther et al. show that Olanzapine-induced hypothermia is
dose dependent (Oerther and Ahlenius, 2000), which probably
accounts also for the reduction of activity when compared to our
data. As seen in Fig. 4 control animals increase their activity and body
temperature at the time of administration, after which there is a
signiﬁcant drop in temperature and activity. Preliminary studies in
our lab revealed that lower doses of Olanzapine will not result in a
signiﬁcant drop of activity and body temperature compared to control
treated animals. In addition, we also noticed that there are remarkable
differences in the effect of olanzapine on metabolism in, male and
female rats, we are currently investigating this. During this study we
have not measured if Olanzapine may decrease both basal metabolic
rate and locomotor activity, Future studies should reveal if Olanzapine
affects both these parameters of energy expenditure.
Based on the data above, we conclude that, in female Wistar rats,
Olanzapine-induced weight gain in this paradigm is primarily the
result of a major reduction in locomotor activity without changes in
24 h daily food intake. These ﬁndings are in line with the data from
human literature in which the sedative effect of Olanzapine is well-
documented (Callaghan et al., 1997; Putzhammer et al., 2005; Roerig
et al., 2005). Evidence in humans for an effect of Olanzapine on food
intake is less consistent (Eder et al., 2001; Gothelf et al., 2002; Roerig
et al., 2005; Stauffer et al., 2009).We also found that Olanzapine has a
dramatic acute effect on body temperature. Data in literature
suggests that this Olanzapine-induced hypothermia is mainly the
result of decreased BAT sympathetic activity, involving the orexin-A
system at the level of the PeF in the LHA. Future studies are needed
to unravel the possible effects of Olanzapine-induced locomotor
inactivity and hypothermia onmeal size, meal frequency and feeding
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